


**[Figure 1] Yearly changes in the percentage of first-line prescriptions (2009–2021 [Excluding 2011])**

DPP-4 inhibitors added since 2010 and SGLT2 inhibitors added since 2015



**[Figure 1] Yearly changes in the percentage of first-line prescriptions (2009–2021 [Excluding 2011] )**

DPP-4 inhibitors added since 2010 and SGLT2 inhibitors added since 2015

	2009 (n=43)	2010 (n=36)	2011	2012 (n=180)	2013 (n=152)	2014 (n=164)	2015 (n=171)	2016 (n=221)	2017 (n=234)	2018 (n=240)	2019 (n=187)	2020 (n=292)	2021 (n=202)
SU	24.1	12.5	-	13	7.7	6.6	4.9	4.2	3.1	3.1	2.2	2.5	2.1
$\alpha$ -GI	18.3	11.3	-	8.1	4.9	4.8	3.9	2.7	2.3	2.5	1.7	2.4	1.7
BG	31.6	38.6	-	33.4	32.6	38.9	36.5	35.5	33.4	34.8	38.1	36.5	39.4
Thiazolidines	10.2	7.6	-	2.7	2.2	1	2	1.1	0.8	1.2	0.5	0.6	0.8
Glinides	9.6	5.1	-	5.5	4.4	2.5	2.5	1.9	1.5	1.7	1.5	1.6	1.4
DPP-4 inhibitors	-	12.6	-	28.5	34	32.4	36.7	40.4	35.9	35.4	33.2	30.9	32.2
Insulin	4	5.3	-	4.1	6.2	5.4	4.8	4.5	5.8	4.7	5.3	4	3.7
Other (e.g., combined use)	2.3	6.3	-	2.9	6	7.3	7.1	6.2	11.6	9.2	7.6	10.7	5.7
GLP-1 agonists	-	0.7	-	2	1.9	1	1	1	1.3	1.6	1.7	2.2	1.7
SGLT2 inhibitors	-	-	-	-	-	-	0.6	2.7	4.3	5.9	8.3	8.6	11.2